All Stories

  1. The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema
  2. The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review
  3. Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting
  4. Expanding the molecular and clinical spectrum of autosomal recessive congenital ichthyosis caused by pathogenic variants in NIPAL4 and PNPLA1 and evaluation of novel therapeutic interventions
  5. Reporting of Harmonising Outcome Measures for Eczema (HOME) core outcome set instruments in randomized clinical trials for systemic treatments in atopic dermatitis
  6. The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study
  7. Effectiveness and patient satisfaction of a Dutch patient decision aid for psoriasis – a pilot study
  8. Measurement instruments for the core outcome set of congenital melanocytic naevi and an assessment of the measurement properties according to COSMIN: a systematic review
  9. A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting
  10. Appearance-related concerns and their impact on health-related quality of life in patients with peripheral vascular malformations
  11. Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review
  12. Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”
  13. Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2*
  14. Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project)
  15. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
  16. The Selection Process for a Web-Based Application to Measure Patient-Reported Outcomes Following the Example of the TREAT NL Registry
  17. Work ability and quality of working life in atopic dermatitis patients treated with dupilumab
  18. Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals
  19. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries
  20. Surgical Treatment of Peripheral Vascular Malformations: A Systematic Review and Meta-Analysis
  21. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts
  22. Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*
  23. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics
  24. Online decision aid for patients with psoriasis
  25. Responsiveness of quality of life measures in children with peripheral vascular malformations: The OVAMA project
  26. Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research*
  27. Phototherapy for atopic eczema
  28. Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*
  29. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
  30. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
  31. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach
  32. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations
  33. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry
  34. Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology‐specific outcome taxonomy
  35. International collaboration and rapid harmonization across dermatologic COVID-19 registries
  36. The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians
  37. Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics
  38. Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic
  39. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis
  40. Generic outcome set for the international registry on Laser trEAtments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on what to measure
  41. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis
  42. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases
  43. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative
  44. Outcomes and measurement instruments used in congenital melanocytic naevi research: A systematic review
  45. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate‐to‐severe atopic eczema*
  46. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema ( RECAP )
  47. Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
  48. Towards More Shared Decision Making in Dermatology: Develop­ment of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments
  49. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group
  50. Responsiveness of quality‐of‐life measures in patients with peripheral vascular malformations: the OVAMA project
  51. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
  52. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data
  53. Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project)
  54. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab
  55. Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review
  56. Finalizing the international core domain set for peripheral vascular malformations: the OVAMA project
  57. Navigating the landscape of core outcome set development in dermatology
  58. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period
  59. TRE atment of AT opic eczema ( TREAT ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries
  60. Cochrane Reviews and Dermatological Trials Outcome Concordance: Why Core Outcome Sets Could Make Trial Results More Usable
  61. Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017
  62. Reversibility of alexithymia with effective treatment of moderate‐to‐severe psoriasis: longitudinal data from EPIDEPSO
  63. Relationship and probabilistic stratification of Eczema Area and Severity Index and objective Scoring Atopic Dermatitis severity scores for atopic dermatitis
  64. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults
  65. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries
  66. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis
  67. Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative
  68. Patient-Reported Outcomes of Bleomycin Sclerotherapy for Low-Flow Vascular Malformations and Predictors of Improvement
  69. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
  70. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial
  71. Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative
  72. By using a core outcome set we measure what matters to patients
  73. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data
  74. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
  75. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project
  76. Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
  77. Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment
  78. Discrepancy between the clinical and histopathologic diagnosis of soft tissue vascular malformations
  79. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries
  80. How to write a Critically Appraised Topic: evidence to underpin routine clinical practice
  81. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council
  82. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
  83. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
  84. Procollagen-3 N -terminal peptide measurements for the detection of liver fibrosis in methotrexate-treated patients with psoriasis: daily practice use and clinical implications
  85. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries
  86. One-stop-shop with confocal microscopy imaging vs. standard care for surgical treatment of basal cell carcinoma: an open-label, noninferiority, randomized controlled multicentre trial
  87. Reporting of outcomes in randomised controlled trials on nail psoriasis; a Systematic Review
  88. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety
  89. Doing Good Research Is Difficult, Doing No Research Is More Difficult
  90. Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study
  91. Pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid: a critically appraised topic
  92. Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
  93. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement
  94. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries
  95. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
  96. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
  97. Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries
  98. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
  99. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field
  100. Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review
  101. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review
  102. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
  103. Global Allergy Forum and 3rd Davos Declaration 2015
  104. Intralesional Bleomycin Injections for Vascular Malformations
  105. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation
  106. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults
  107. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC
  108. Diphencyprone treatment in patients with alopecia areata
  109. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial
  110. In vivo confocal microscopy of basal cell carcinoma: a systematic review of diagnostic accuracy
  111. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting
  112. Clearing up misunderstandings around core outcomes for atopic dermatitis
  113. Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis
  114. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres
  115. Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
  116. A national study on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline adherence
  117. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal
  118. Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review
  119. The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology
  120. The IL-17A-Producing CD8 + T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells
  121. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)
  122. Combined Use of Systemic Agents for Psoriasis
  123. Prospective registration of clinical trials published in the B ritish J ournal of D ermatology
  124. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
  125. An increased risk of non‐melanoma skin cancer during TNF‐inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease‐related factors
  126. Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR + ILC3 in Lesional Skin and Blood of Psoriasis Patients
  127. Prioritizing dermatoses: rationally selecting guideline topics
  128. Critically Appraised Topics in the British Journal of Dermatology : response from Jonathan Batchelor and Phyllis Spuls, section editors for BJD 's ‘Put...
  129. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single‐centre database analysis
  130. Treatment of Psoriasis
  131. Evaluation of a Tertiary Teledermatology Service Between Peripheral and Academic Dermatologists in The Netherlands
  132. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research
  133. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review
  134. Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis
  135. Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation
  136. Comment on ‘Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study’
  137. The European treatment of severe atopic eczema in children taskforce (TREAT) survey
  138. Accuracy and reliability of teledermatoscopy with images taken by general practitioners during everyday practice
  139. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries
  140. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic
  141. Interventions for nail psoriasis
  142. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial
  143. Measurement Properties of Outcome Measures for Vitiligo
  144. The prevalence of thyroid disease in patients with vitiligo: a systematic review
  145. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal
  146. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting
  147. Health-Related Quality-of-Life Assessment in Dermatologic Practice: Relevance and Application
  148. Response to a randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal
  149. Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies
  150. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review
  151. Teledermatology applied following patient selection by general practitioners in daily practice improves efficiency and quality of care at lower cost
  152. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men
  153. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference
  154. A randomized trial of methotrexate versus azathioprine for severe atopic eczema
  155. A randomized comparison of excimer laser versus narrow‐band ultraviolet B phototherapy after punch grafting in stable vitiligo patients
  156. Survival in cancer patients hospitalized for psoriasis: a commentary
  157. Prospective comparison of three guideline development methods for treatment of actinic keratosis
  158. Off-label Use of Azathioprine in Dermatology
  159. Validation and refinement of the Millennium Criteria for atopic dermatitis
  160. Etanercept
  161. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges
  162. A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists
  163. Evaluation of and Perspectives on Guidelines: What Is Important?
  164. Off-label use of efalizumab in dermatology
  165. Definition of treatment goals for moderate to severe psoriasis: a European consensus
  166. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
  167. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot
  168. How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review
  169. Is there a rural/urban gradient in the prevalence of eczema? A systematic review
  170. Atopic eczema or atopiform dermatitis
  171. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
  172. Tertiary Teledermatology: A Systematic Review
  173. Experience with biologics for psoriasis in daily practice: switching is worth a try
  174. The burden of vitiligo: Patient characteristics associated with quality of life
  175. The Misperception That Clinical Trial Data Reflect Long-term Drug Safety
  176. A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: ‘AGREE-ing’ on a common base for European evidence-based psoriasis treatment guidelines
  177. Interventions for nail psoriasis
  178. National Registries of Systemic Treatment for Psoriasis and the European ‘Psonet’ Initiative
  179. STROBE
  180. Topical treatments in psoriasis: today and tomorrow
  181. Controversies in Atopic Dermatitis
  182. Clinical Differences between Atopic and Atopiform Dermatitis
  183. A Review of the Literature for Nail Psoriasis
  184. Retrospective study of the efficacy of narrowband UVB and acitretin
  185. Nonsurgical Repigmentation Therapies in Vitiligo
  186. A systematic review of five systemic treatments for severe psoriasis: Reply
  187. A systematic review of five systemic treatments for severe psoriasis
  188. Treatment of generalized bullous pemphigoid with topical corticosteroids.